Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Asset Dedication LLC

Asset Dedication LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,638 shares of the biopharmaceutical company's stock after buying an additional 6,217 shares during the period. Asset Dedication LLC's holdings in Gilead Sciences were worth $1,416,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the period. Core Alternative Capital increased its position in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Finally, Lee Danner & Bass Inc. purchased a new position in Gilead Sciences during the fourth quarter worth about $41,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 1.8%

Shares of NASDAQ GILD traded up $1.95 during mid-day trading on Monday, hitting $111.59. The company had a trading volume of 2,216,362 shares, compared to its average volume of 7,681,433. Gilead Sciences, Inc. has a 1-year low of $70.21 and a 1-year high of $119.96. The company has a market capitalization of $138.81 billion, a PE ratio of 23.51, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The business's 50-day simple moving average is $107.74 and its 200 day simple moving average is $104.75.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the business posted ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.83%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares in the company, valued at $18,190,168.70. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer directly owned 615,725 shares of the company's stock, valued at $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,500 shares of company stock valued at $6,340,745. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Nine research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.